(PharmaNewsWire.Com, January 09, 2021 ) The key factors driving the growth of this market include the rising prevalence of cardiovascular diseases, increasing number of regulatory approvals, and a huge gap between supply and demand of donor hearts is driving the demand for heart pump devices.
According to MarketsandMarkets Research "Heart Pump Device Market by Product (Ventricular Assist Device (LVAD, RVAD, BiVAD, and pVAD), Intra Aortic Balloon Pump, TAH), Type (Extracorporeal and Implantable Pump), Therapy (Bridge-to-transplant, Destination Therapy) - Global Forecast", is projected to reach USD 3.98 Billion, at a CAGR of 19.4% during the forecast period.
Objectives of the Study;
# To define, measure, and describe the global heart pump devices market by product, type, therapy, and region
# To provide detailed information about the major factors influencing market growth (drivers, restraints, challenges, and opportunities)
# To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
# To forecast the size of market segments in North America, Europe, Asia Pacific, and RoW
On the basis of product, the heart pump devices market is segmented into ventricular assist devices, intra-aortic balloon pumps, and total artificial heart. The ventricular assist devices segment is expected to account for the largest share of the global market. The large share of this segment can be primarily attributed to the high prevalence of heart failure across the globe.
On the basis of therapy, the heart pump devices market is segmented into bridge-to-transplant, bridge-to-candidacy, destination therapy, and other therapies (bridge-to-recovery and rescue therapy). The bridge-to-candidacy segment is expected to account for the largest share of the global market. The large share of this segment can be primarily attributed to the effective treatment decisions and patient outcomes associated with bridge-to-candidacy.
Geographic segments in this report include North America, Europe, Asia Pacific, and RoW. Of these, the North American segment is expected to account for the largest share of the heart pump devices market. The large share of this region can primarily be attributed to the rising prevalence of cardiovascular diseases, favorable reimbursement scenario, and the increasing number of regulatory approvals. The high cost of devices and implantation procedures and poor reimbursement scenario in developing countries is expected to restrain the growth of this market during the forecast period. For instance, in emerging countries such as China and India, no coverage is provided for heart pump devices, thus increasing the out-of-pocket expenditure by patients.
The key players in the global heart pump devices market are St. Jude Medical (a subsidiary of Abbott Laboratories) (US), Abiomed (US), Medtronic (Ireland), Getinge (Sweden), Teleflex (US), ReliantHeart (US), BerlinHeart (Germany), Terumo (Japan), SynCardia Systems (US), TandemLife (CardiacAssist) (US), Jarvik Heart (US), and Fresenius Medical Care (Germany).
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
